1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Colon Carcinoma - Pipeline Review, H1 2014

Colon Carcinoma - Pipeline Review, H1 2014

  • March 2014
  • -
  • Global Markets Direct
  • -
  • 45 pages

Colon Carcinoma - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Colon Carcinoma - Pipeline Review, H1 2014’, provides an overview of the Colon Carcinoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Colon Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Carcinoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Colon Carcinoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Colon Carcinoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Colon Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Colon Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Colon Carcinoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Colon Carcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Colon Carcinoma - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Colon Carcinoma Overview 6
Therapeutics Development 7
Pipeline Products for Colon Carcinoma - Overview 7
Pipeline Products for Colon Carcinoma - Comparative Analysis 8
Colon Carcinoma - Therapeutics under Development by Companies 9
Colon Carcinoma - Therapeutics under Investigation by Universities/Institutes 10
Colon Carcinoma - Pipeline Products Glance 12
Early Stage Products 12
Colon Carcinoma - Products under Development by Companies 13
Colon Carcinoma - Products under Investigation by Universities/Institutes 14
Colon Carcinoma - Companies Involved in Therapeutics Development 15
Philogen S.p.A. 15
AIMM Therapeutics B.V. 16
Synergys Biotherapeutics, Inc. 17
Colon Carcinoma - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
CIGB-247 Vaccine - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Antibody for Oncology - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Small Molecules to Inhibit Tubulin for Oncology - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Monoclonal Antibodies for Gastrointestinal Diseases - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
Anti-EGFR-ATEP - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Methoxynaphthylfenoterol - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Salmonella Based Cancer Vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
IL-2 Therapy - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Adhesio-mAb - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Anti-MFG-E8 Mab - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
F8IL-4 - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Antibody to Inhibit Rspo2 and Rspo3 for Oncology - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
DR5-Receptor Specific TRAIL Mutant Protein - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
Colon Carcinoma - Dormant Projects 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 45
Disclaimer 45

List of Tables

Number of Products under Development for Colon Carcinoma, H1 2014 7
Number of Products under Development for Colon Carcinoma - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Products under Investigation by Universities/Institutes, H1 2014 14
Colon Carcinoma - Pipeline by Philogen S.p.A., H1 2014 15
Colon Carcinoma - Pipeline by AIMM Therapeutics B.V., H1 2014 16
Colon Carcinoma - Pipeline by Synergys Biotherapeutics, Inc., H1 2014 17
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Stage and Target, H1 2014 20
Number of Products by Stage and Mechanism of Action, H1 2014 22
Number of Products by Stage and Route of Administration, H1 2014 24
Number of Products by Stage and Molecule Type, H1 2014 26
Colon Carcinoma - Dormant Projects, H1 2014 43

List of Figures

Number of Products under Development for Colon Carcinoma, H1 2014 7
Number of Products under Development for Colon Carcinoma - Comparative Analysis, H1 2014 8
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Early Stage Products, H1 2014 12
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Top 10 Target, H1 2014 19
Number of Products by Stage and Top 10 Target, H1 2014 20
Number of Products by Top 10 Mechanism of Action, H1 2014 21
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 22
Number of Products by Top 10 Route of Administration, H1 2014 23
Number of Products by Stage and Top 10 Route of Administration, H1 2014 24
Number of Products by Top 10 Molecule Type, H1 2014 25
Number of Products by Stage and Top 10 Molecule Type, H1 2014 26

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Brain Cancer: Analytical Tool

August 2016 $ 8096

Breast Cancer: Analytical Tool

August 2016 $ 8096

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.